Review Article| Volume 6, ISSUE 1, P43-52, May 2023

Download started.


Use of Tranexamic Acid for Melasma


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Advances in Cosmetic Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Zhu Y.
        • Zeng X.
        • Ying J.
        • et al.
        Evaluating the quality of life among melasma patients using the MELASQoL scale: a systematic review and meta-analysis.
        PLoS One. 2022; 17: e0262833
        • Rajanala S.
        • Maymone M.B.C.
        • Vashi N.A.
        Melasma pathogenesis: a review of the latest research, pathological findings, and investigational therapies.
        Dermatol Online J. 2019; 25
        • McKesey J.
        • Tovar-Garza A.
        • Pandya A.G.
        Melasma treatment: an evidence-based review.
        Am J Clin Dermatol. 2020; 21: 173-225
        • Kimbrough-Green C.K.
        • Griffiths C.E.
        • Finkel L.J.
        • et al.
        Topical retinoic acid (tretinoin) for melasma in black patients: a vehicle-controlled clinical trial.
        Arch Dermatol. 1994; 130: 727-733
        • Jusuf N.K.
        • Putra I.B.
        • Mahdalena M.
        Is there a correlation between severity of melasma and quality of life?.
        Open Access Maced J Med Sci. 2019; 7 (in eng): 2615-2618
        • Balkrishnan R.
        • et al.
        Development and validation of a health-related quality of life instrument for women with melasma.
        Br J Dermatol. 2003; 149: 572-577
        • Watts G.
        Utako Okamoto.
        Lancet. 2016; 387: 2286
        • "World Health
        Organization model list of essential medicines, 22nd list, 2021.
        World Health Organization, Geneva2021
      1. J.M. Chauncey. In: J.S. editor, Wieters, Tranexamic acid, StatPearls, StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC., Treasure Island (FL), 2022.

        • Wang K.
        • Geiger H.
        • McMahon A.
        Tranexamic acid for ACE inhibitor induced angioedema.
        Am J Emerg Med. 2021; 43: 292.e5-292.e7
        • Perper M.
        • et al.
        Tranexamic acid in the treatment of melasma: a review of the literature.
        Am J Clin Dermatol. 2017; 18: 373-381
        • Bala H.R.
        • Lee S.
        • Wong C.
        • et al.
        Oral tranexamic acid for the treatment of melasma: a review.
        Dermatol Surg. 2018; 44
      2. Lysteda (tranexamic acid) package insert. Ferring Pharmaceuticals Inc., Parsippany, NJ2020
      3. Cyklokapron (tranexamic acid) package insert. Pfizer Injectables, New York, NY2021
        • Murdaca G.
        • Greco M.
        • Vassallo C.
        • et al.
        Tranexamic acid adverse reactions: a brief summary for internists and emergency doctors.
        Clin Mol Allergy. 2020; 18 (in eng): 16
        • Chornenki N.L.J.
        • et al.
        Risk of venous and arterial thrombosis in non-surgical patients receiving systemic tranexamic acid: a systematic review and meta-analysis.
        Thromb Res. 2019; 179: 81-86
        • Taeuber I.
        • et al.
        Association of intravenous tranexamic acid with thromboembolic events and mortality: a systematic review, meta-analysis, and meta-regression.
        JAMA Surgery. 2021; 156: e210884
        • Kim S.J.
        • Park J.Y.
        • Shibata T.
        • et al.
        Efficacy and possible mechanisms of topical tranexamic acid in melasma.
        Clin Exp Dermatol. 2016; 41: 480-485
        • Maeda K.
        • Naganuma M.
        Topical trans-4-aminomethylcyclohexanecarboxylic acid prevents ultraviolet radiation-induced pigmentation.
        J Photochem Photobiol B Biol. 1998; 47: 136-141
        • Yuan C.
        • Wang X.-M.
        • Yang L.-J.
        • et al.
        Tranexamic acid accelerates skin barrier recovery and upregulates occludin in damaged skin.
        Int J Dermatol. 2014; 53: 959-965
        • Hiramoto K.
        • Sugiyama D.
        • Takahashi Y.
        • et al.
        The amelioration effect of tranexamic acid in wrinkles induced by skin dryness.
        Biomed Pharmacother. 2016; 80: 16-22
        • Tohgasaki T.
        • et al.
        Enolase-1 expression in the stratum corneum is elevated with parakeratosis of atopic dermatitis and disrupts the cellular tight junction barrier in keratinocytes.
        Int J Cosmet Sci. 2018; 40: 178-186
        • Sonoki A.
        • Okano Y.
        • Yoshitake Y.
        Dermal fibroblasts can activate matrix metalloproteinase-1 independent of keratinocytes via plasmin in a 3D collagen model.
        Exp Dermatol. 2018; 27: 520-525
        • Na J.I.
        • Choi S.Y.
        • Yang S.H.
        • et al.
        Effect of tranexamic acid on melasma: a clinical trial with histological evaluation.
        J Eur Acad Dermatol Venereol. 2013; 27: 1035-1039
        • Kim E.H.
        • Kim Y.C.
        • Lee E.-S.
        • et al.
        The vascular characteristics of melasma.
        J Dermatol Sci. 2007; 46: 111-116
        • Taraz M.
        • Niknam S.
        • Ehsani A.H.
        Tranexamic acid in treatment of melasma: a comprehensive review of clinical studies.
        Dermatol Ther. 2017; 30: e12465
        • Feng X.
        • Su H.
        • Xie J.
        Efficacy and safety of tranexamic acid in the treatment of adult melasma: An updated meta-analysis of randomized controlled trials.
        J Clin Pharm Ther. 2021; 46: 1263-1273
        • Tan A.W.M.
        • Sen P.
        • Chua S.H.
        • et al.
        Oral tranexamic acid lightens refractory melasma.
        Australas J Dermatol. 2017; 58: e105-e108
        • Del Rosario E.
        • et al.
        Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma.
        J Am Acad Dermatol. 2018; 78: 363-369
        • Wu S.
        • et al.
        Treatment of melasma with oral administration of tranexamic acid.
        Aesthetic Plast Surg. 2012; 36: 964-970
        • Choi Y.K.
        • et al.
        Effects of vitamin C vs. multivitamin on melanogenesis: comparative study in vitro and in vivo.
        Int J Dermatol. 2010; 49: 218-226
        • Lee H.C.
        • Thng T.G.S.
        • Goh C.L.
        Oral tranexamic acid (TA) in the treatment of melasma: a retrospective analysis.
        J Am Acad Dermatol. 2016; 75: 385-392
        • Sadako N.
        Treatment of melasma with tranexamic acid.
        Clim Rep. 1979; 13: 3129-3131
        • Cho H.H.
        • Choi M.
        • Cho S.
        • et al.
        Role of oral tranexamic acid in melasma patients treated with IPL and low fluence QS Nd:YAG laser.
        J Dermatolog Treat. 2013; 24: 292-296
        • Shin J.U.
        • Park J.
        • Oh S.H.
        • et al.
        Oral tranexamic acid enhances the efficacy of low-fluence 1064-nm quality-switched neodymium-doped yttrium aluminum garnet laser treatment for melasma in koreans: a randomized, prospective trial.
        Dermatol Surg. 2013; 39
        • Thieman T.
        • Swali R.
        • Adams J.
        33031 Use of topical tranexamic acid in patients with melasma: a narrative review.
        J Am Acad Dermatol. 2022; 87: AB126
        • Kanechorn Na Ayuthaya P.
        • Niumphradit N.
        • Manosroi A.
        • et al.
        Topical 5% tranexamic acid for the treatment of melasma in Asians: a double-blind randomized controlled clinical trial.
        J Cosmet Laser Ther. 2012; 14: 150-154
        • Budamakuntla L.
        • et al.
        A randomised, open-label, comparative study of tranexamic acid microinjections and tranexamic acid with microneedling in patients with melasma.
        J Cutan Aesthet Surg. 2013; 6: 139-143
        • Sahu P.
        • Dayal S.
        • Bhardwaj N.
        Topical 5% tranexamic acid with 30% glycolic acid peel: An useful combination for accelerating the improvement in melasma.
        Dermatol Ther. 2021; 34: e15107
        • Wang J.V.
        • Jhawar N.
        • Saedi N.
        Tranexamic Acid for Melasma: Evaluating the Various Formulations.
        J Clin Aesthet Dermatol. 2019; 12 (E73–e74)
        • Banihashemi M.
        • Zabolinejad N.
        • Jaafari M.R.
        • et al.
        Comparison of therapeutic effects of liposomal Tranexamic Acid and conventional Hydroquinone on melasma.
        J Cosmet Dermatol. 2015; 14: 174-177
        • Ebrahimi B.
        • Naeini F.F.
        Topical tranexamic acid as a promising treatment for melasma.
        J Res Med Sci. 2014; 19: 753-757
        • Lueangarun S.
        • et al.
        Intradermal tranexamic acid injection for the treatment of melasma: a pilot study with 48-week follow-up.
        J Clin Aesthet Dermatol. 2020; 13: 36-39
        • Lee J.H.
        • et al.
        Localized intradermal microinjection of tranexamic acid for treatment of melasma in asian patients: a preliminary clinical trial.
        Dermatol Surg. 2006; 32: 626-631
        • Steiner D.
        • et al.
        Study evaluating the efficacy of topical and injected tranexamic acid in treatment of melasma.
        Surg Cosmet Dermatol. 2009; 1